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The phospholipase A2 (PLA2) activities that are localized in 
the keratinocyte cytosolic and microsomal fractions were 
biochemically and pharmacologically characterized. The cy-
tosol and to a lesser extent the microsome were sensitive to 
heat treatment and stable in the presence of sulfhydryl reduc-
ing agents. Both fractions were almost totally inactivated by 
reduction of pH to 2. The cytosolic activity demonstrated a 
sevenfold preference for arachidonic acid over oleic acid in 
the sn-2 position of substrate phospholipid and the micro-
some exhibited a fourfold preference. N either the cytosol nor 
the microsome was inactivated by a neutralizing mouse 
monoclonal antibody 3FI0 generated against recombinant 
human (rh) type II 14-kDa PLA2. Western immunoblot 
analysis of both fractions identified a high - molecular-mass 
protein in keratinocyte cytosol but not the microsome that 
migrated with rh 85-kDa PLA2. Neither the sytosol nor the 
microsome possessed immunoreative bands that migrated 
with rh type II 14:-kDa PLA2 when probed with monoclonal 
T he keratinocyte generates a variety of lipid mediators, i.e., the prostanoids, prostaglandins E2 (PGE2) and D2 [1,2]' the hydroxy fatty acids; 5-hydroxyeicosate-traenoic acid (HETE), 12-HETE, and 15-HETE [3,4]' and recent reports suggest that, if supplied with 
the precursor leukotriene (LT) A4, keratinocytes can form LTB4 [5]. 
The prostanoids are believed to be involved in the excessive epider-
mal proliferation characteristic of psoriasis [6] and the monohy-
droxy fatty acids participate in the inflammatory process of the 
skin [7] . 
Phospholipase A2 (PLA2; EC 3.1.1.4) is the rate-limiting enzyme 
responsible for liberation of arachidonic acid (AA), which is subse-
quently metabolized to eicosanoids. Two mammalian PLA2 iso-
forms, the 14-kDa PLA2 and the 85-kDa PLA2 [8-10], have been 
characterized and although they are structurally and catalytically 
distinct they share many of the same properties. The characteristics 
of the SI1-2 acylhydrolase activities described in the epidermis [11-
14] or various skin cells, e. g., keratinocytes [11] and Langerhans 
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antibody 3FI0. Further analysis of the cytosolic aCtiVIty 
showed that it was activated by submicromolar concentra-
tions of Ca2+, reduced by arachidonyl trifloromethylketone, 
a selective 85-kDa PLA2 inhibitor, but was unaffected by C-7 
phosphonate phospholipid, a selective 14-kDa PLA2 transi-
tion state inhibitor. Taken together, the data supports the 
existence of a PLA2 activity in the cytosol that displays char-
acteristics that are indistinguishable from those exhibited by 
the 85-kDa PLA2. Alternatively, both the cytosol and micro-
some were devoid of type II 14-kDa -like PLA2 activity. The 
failure of 12-epi scalaradial, a 14-kDa PLA2 inhibitor, to 
modify A23187-stimulated keratinocyte prostaglandin E2 
release, was consistent with the biochemistry and suggests 
that the 85-kDa PLA2 may play an important role in kerati-
nocyte prostaglandin E2 formation. Key words: arachidonic 
acid/phospholipase A 2/keratinocyte/prostaglandin E2/indometha-
cin/scalaradial/inhibitor.] Invest Dermatol1 02:980- 986, 1994 
cells [15], are those shared by both isoforms. This includes neutral to 
alkaline pH activity, hydrolysis from the s~I-2 position of phospho-
lipid (PL) substrate, and activation by submicromolar concentra-
tions of Ca++. Alternatively, the 85-kDa PLA2 is distinct from the 
14-kDa PLA2 in that it exhibits a preference for AA over other fatty 
acids, requires Ca++ for binding to membrane but not for catalysis 
[16], exhibits Ca++-independent Iysophospholipase activity [16], is 
phosphorylated [8] , and is sensitive to treatment with heat [9,16] or 
acid l17]. Recently, a cytosolic PLA2 was described in HEL-30 kera-
tinocytes that was phosphorylated at a low intracellular Ca++ con-
centration and migrated to the membrane upon exposure to trans-
forming growth factor-a (TGF-a) [18]. Although this suggests the 
possible presence of the 85-kDa PLA2 , to date the SI1-2 acyl hydro-
lases residing in the keratinocyte have not been fully characterized 
with respect to the human type II 14-kDa PLA2 or 85-kDa PLA2, 
nor has their role in keratinocyte prostaglandin formation been 
clearly elucidated. 
The following studies were carried out to characterize the SI1-2 
acyl hydrolase activity of cultured human keratinocytes using bio-
chemical, immunologic, and pharmacologic tools that distinguish 
between the type II 14-kDa and the U937 85-kDa PLA2 [16]. The 
activities assessed predominantly exhibited an s~I-2 acyl hydrolase 
activity identical to the 85-kDa PLA2. Further, no type II 14-kDa-
like PLA2 activity could be identified biochemically and PGE2 re-
lease was unaffected by a selective 14-kDa PLA2 inhibitor, which 
was consistent with our characterization. This supports the possibil-
ity that the 85-kDa-like PLA2 may playa role in prostanoid forma-
tion. 
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MATERIALS AND METHODS 
Materials and Chemicals [14C]1 -stearoyl-2-arachidonyl phosphatidyl-
holine (PC) (54 mCI/mmol) was purchased from Amersham (Boston. ~). [3H]-AA-labeled EsciJ ericiJia coli (0.5 pCi/8 nmol Pi) and [14C]l-pal-
mitoyl-2-0Ieoyl PC (58 mCi/mmol) were purchased from N ew England 
N uclear (Arlington Heights. IL). Phosphate-buffered sal ine (PBS) was ob-
tained from GIBCO (Grand Island, N Y). Ethylene glycol-bis-(p-amin-
oeth yl ether)-N,N ,N'N' / tetraacetic acid (EGT ~), phenylmeth~lsulfonyl 
fl uor ide (PMSF), leupeptlll , soybean trypSlll lllillbltor, and aprotlllln were 
urchased from Sigma Chemical Co. (St. Louis, MO) . Aminopropyl (NH2) 
PoJid-phase silica columns 9070 (100 mg/ ml) were obtained from Burdick 
:nd Jackson (Muskeogon, MI). C-7 phosphonate phospholipid (C-7 PP) 
t4-kDa-PLA2 transition-state inhibitor (TSA) and trifluoromethyl ketone (TFMK) were kindly donated by Dr. Micheal Gelb, University of Washing-
ton (Seattle, WA) [19,20]. 12-epi-scalaradial (Sa, 12a, 17aP,)-12-(acetyl-
oxy)_4 ,4,8-trimethyl-D-homoandrost-1 6-ene-17, 17a -dicarboxaldehyde 
urified from the sponge (Cacospollgia mol/ior) (catalogue number ST-350, 
LotJ 1218) was purchased from Biomol (Plymouth Meeting, PAl [21]. Dex-
arnethasone (catalogue number D-1756, Lot 104F-01 63) was purchased 
from Sigma Chemical Co. (St. Louis, MO). Indomethacin was generously 
donated by Merck Sharp and Dohme (Rahway, NJ) and zileuton [A-64077; 
N _hydroxy-N-(1-benzol[b]thien-2-ylethyl)urea] was synthesized by the 
Department of Medicinal Chemistty, SmithKline Beecham Pharmaceuti-
cals (King of Prussia, PAl· 
preparation of Purified Human Phospholipase A. Enzymes 
Recombinant human (rh) type II 14-kDa PLA2 cloned from placenta mRNA 
was expressed as an authentic processed enzyme in CHO cells and purified 
essentially by literature m.ethods w ith some modificati~n.s as previously 
describe d [22,23]. The punfied enzyme had a speCific actlVlty of200 -300 
prrloljmg/min in an [3H]_AA Esc!zeric!lia coli assay and was biochemically 
indistingUishable from the enzyme purified from human synOVial flUid [23]. 
V937 85-kDa PLA2 was purified from the cytosol of the human leukemic 
monoblast U937 cell line as previously described [24]. The enzyme was 
purified through the high-salt Phenyl Superose column and then concen-
trated on a Mono Q HR 5/5 column yielding a final specific activity of240 
nrnol/mg/ l0 min in a (3H]-AA E. coli assay. Recombinant material was 
repared using a U937 85-kDa PLA2 cDNA subcloned into the baculovirus ~ector pAcCL29 and infection of Sp%ptera frugiperde (SF21) cells as previ-
ously described [25] . 
Preparation of Mouse Anti-rh Type II PLA. Monoclonal Antibody 
(3FI0) and rh 85-kDa PLA. Rabbit Antiserum The neutralizing 
monoclonal antibody (MoAb) SK097-3F10 (3FI0) was selected from a panel 
of antibodies generated to rh type II 14-kDa PLA2. CAFI female mice 
(Charles River Portage, Wil~ington, MA) were immunized by three sub-
cutaneous injections of rh type II 14-kDa PLA2 (100, 50, and 25 p g, respec-I nvely) in Freund's complete adjuvant at 4-week intervals. Immune mice, 
selected on the basis of serum titer to the immunizing antigen, were boosted I intravenously with rh type II 14-kDa PLA2 for three consecutive days prior 
to removal of their spleens. Spleen cells were fused with SP2/0-AG 14 I myeloma cells and hybrids were selected using HAT (hypoxanthine, amin-
opterin, thymidine) -containing medium, as described previously [26]. Cul-I ture supernatants of hybrids were screened for anti-PLA2 activity and the 
I
, lack of cross reactivity with serum albumin, a variety of inflammatory cyto-
kines and other PLA2 enzymes such as those from snake venom, the pancre-
t atic PLA2, or the rat kidney PLA2, using a standard solid-phase enzyme-
, linked immunosorbent assay. The 3FI0 antibody was purified from the 
supernatant of a doubly cloned sub-line by protein A chromatography and I was isotyped as an IgG lK. N eutralization studies were carried out by expos-
( 
ing the purified enzyme or cel l fractions to 1- 10 ttg MoAb for 60 min at 
37°C in enzyme assay buffer. 3H-AA-E. coli substrate was then added to 
" measure sll-2 acyl hydrolytic activity as described below. Rabbit polyclonal 
antisera against the E. coli - expressed rh 85-kDa PLA2 was prepared as foi-
I lows. Two 4.0-kg male N ew Zealand white rabbits were immunized with 
I 50 J.lg of protein solubilized in 10 ml sterile phosphate-buffered saline (PBS). ! The enzyme solution was mixed with an equal amount of Freund's complete 
adjuvant until a thick emulsion was formed and administered as 50 1-pg 
I intradermal injections. Rabbits were injected on a 3-week schedule by sub-scapular il~ection of 50 p g antigen in 500 ttl PBS and an equal volume of 
,I Freund's incomplete adjuvant. Serum was collected 1 week after the boost. 
ImlD.unoblot Analysis Keratinocyte cell fractions were analyzed (25-
100 J.lg protein) by sodium dodecylsulfate-polyacrylamide gel electropho-
resis [10-20% gradient gels, Integrated Separation Systems (Natick, MA)], 
transferred to nitrocellulose paper, incubated with appropriate MoAb (3Fl 0) 
or antisera (NS1}(1:500-1 :1000, respectively) , and then incubated with 
sheep anti-mouse or donkey anti-rabbit IgG conjugated to horseradish per-
KERATINOCYTE 85-kDa-LiKE PHOSPHOLIPASE A2 981 
oxidase (1:5000) (Boehringer Mannheim, Indianapolis, IN). Detection of 
immunoreactive bands was carried out using the ECL Western blotting 
system (Amersham, Arlington Heights, IL). Selectivity of the respective 
antibodies was evident with their fai lure to detect other PLA2 enzymes 
included in the immunoblots (data not shown). In addition, preincubation of 
the 85-kDa PLA2 rabbit antisera with antigen (either U 937 monocyte cyto-
sol or baculovirus-expressed 85-kDa PLA2 interfered with its ability to bind 
and detect rh 85-kDa PLA2 protein, which migrates at 110 kDa in our 
system (data not shown). 
Human Foreskin Keratinocyte Culture and Eicosanoid Release 
Assay Human neonatal foreskin keratinocytes were purchased from 
C lone tics Corporation (San Diego, CAl and grown as a monolayer at 37°C, 
5% CO2 in keratinocyte growth medium (KGM), a defined serum-free, 
low-calcium medium containing bovine pituitary extract, epidermal growth 
factor, hydrocortisone, and insulin (Clonetics Corp., San Diego, CAl 
[27,28]' 
Eicosanoid studies were performed using second-passage cells seeded in 
24-well plates. Upon reaching confluency the culture media was removed 
from wells and the cells were washed twice w ith 500 pi PBS without Ca++ 
and Mg++. Phosphate-buffered saline with Ca++ and Mg++ (250 pi/well) 
was added to the cells, followed by the addition of vehicle or drug for a 
10-min incubation at room temperature. Dimethylsulfoxide vehicle was 
never used above 1 %. The cells were then stimulated with A23187 (1 pM) 
for 15 min at 37"C. The reaction was terminated by acidification with 0.02 
M citric acid (10 pi/well) and removal of media. Cell viability was moni-
tored before and after experiments using ttypan blue exclusion. The cell-free 
media was collected and stored at -70· C un ti l analyzed. Cells were scraped 
and protein concentration in each well determined. An average of 1.2 pg 
protein/well was observed. Wells deviating from this number were not 
used. Prostaglandin E2 was directly measured in cell-free media using en-
zyme immunoassay kits purchased from Advanced Magnetics (Cambridge, 
MA). Sample or standard dilutions were made with culture media and ana-
lyzed in duplicate. Results were obtained by extrapolation from a standard 
curve prepared in the media and expressed as pg or ng/ml of sample. 
Keratinocyte Subcellular Fractionation Cells in their second passage, 
reaching 70 -90% confluency, were harvested by trypsinization and cen-
trifugation. The keratinocyte pellet (0.2-1.2 X 108 cells) was resus-
pended in 1-2 ml of homogenization buffer containing 0.34 M sucrose, 
10 mM HEPES, pH 7.4, 1 111M ethyleneglycol-bis(P-aminoethyl ethes)-
N ,N .N' ,N' - tetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 200 pM 
leupeptin, 20 pg/ml soybean trypsin inhibitor, and 20 p g/ml aprotinin at 
4°C. The cell suspension was disrupted by nitrogen cavitation (450 lb/in2 
for 15 min at 4°C) and the homogenate was centrifuged at 400 Xg for 10 
min at 4°C to remove unbroken cells and debris. The resulting supernatant 
fraction was centrifuged at 100,000 X g for 60 min at 4°C to obtain the 
supernatant (cytosolic) and particulate (microsomal) fractions [29,30]. The 
mlcrosomes were resuspended in homogenization buffer and both fractions 
were divided into aliquots, fl ash frozen with liquid N 2, and stored at-70·C 
until analysis . 
Phospholipase A. Enzyme Assay Phospholipase A2 activity of isolated 
purified enzymes (rh 14 or 85-kDa PLA2) or keratinocyte subcellular frac-
tions (20 -200 p g protein per assay) was routinely measured using [3H]-AA 
E. coli substrate (which is readily hydro lyzed by both forms ofPLA2 [1 9]) as 
previously described [31] . The reaction mixture (50 pi total volume) con-
tained 25 mM HEPES, pH 7.4, 150 mM N aCl, 5 mM CaCI2, and 100 pM 
[3H]-AA- labeled E. coli [5 nmollipid phosphorus (Pi) per assay]. Dimethyl-
sulfoxide vehicle or drug solubilized in DMSO was added as no greater than 
10% of the tota l assay volume. This concentration ofDMSO had no adverse 
effects on enzyme activity. All drugs or vehicle were added and incubated for 
10 min at 27°C prior to substrate addition unless otherwise stated. The assay 
was initiated by the addition of substrate and samples were incubated at 37 °C 
for a time predetermined to be on the linear portion of a time versus hydroly-
sis plot (purified enzymes were assayed over 10 min; cell fractions were 
assayed over 60 -90 min) . Reactions were terminated by the addition of 1.0 
ml tetrahydrofuran. Free fatty acid was exclusively separated by elution of 
the sample over an aminopropyl solid-phase si lica columns with tetrahydro-
furan: acetic acid (49: 1 v /v) and quantitated by liquid scintillation counting. 
Results are expressed as percent of free fatty acid hydrolyzed (i.e., [dpm 
generated - background (non-specific hydrolysis) dpm} divided by total 
dpm added] X 100). Background counts were never more than 1 % of the 
total counts added. Specific activity is expressed as pmol free fa tty acid 
hydrolyzed/mg/min. 
Free calcium concentrations were controlled by using Ca++ levels added to 
1 mM ethyleneglycol-bis(p-aminoethyl ether}-N,N,N',N '-tetraacetic acid 
(EGTA) buffers as calculated by the Cation-Ligand Binding Program, IBM 
PC version 9.0 [32,33]. The following amount of Ca++ was added to HEPES 
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buffer (pH 7.4) providing the amount of "free" Ca++ in the parenthesis, i.e., 
o mM (0 mM), 4.65 mM (500 nM), 5.5 roM (100 jlM), 10 mM) (1 mM). The 
Ca++ concentrations of the assay buffers were determined using the fluores-
cent calcium indicator fura-2 (Behring Diagnostics, San Diego, CAl [34] for 
less than 1 jlM and by Inductively Coupled Plasma (ICP) spectrometry using 
a Jobin-Yvan model 38 spectrometer (393.4 or 317 nm wavelength) or by 
using an Orion Model 90-01 single junction reference Ca++ electrode (Bos-
ton, MA) for 1 jlM and above. To obtain zero Ca++ in buffers a multivalent 
ion chelator had to be present. 
To assess sn-2 fatty acyl preference, vesicles of 1-palmitoyl-2-[l4C] arachi-
donyl or I-stearoyl-2-[14C] oleoyl PC at equal Pi concentrations (3.4 nM 
Pi/assay) were prepared as previously described [34]. Briefly, vesicles were 
formed by drying PC under a continuous stream of nitrogen, resuspending 
in assay buffer, and sonicating with a probe tip Bronson Sonifier sonicator (5 
seconds) on ice. The subcellular fractions were then assayed for activity as 
described above. 
Protein Determination All protein concentrations were determined by 
Bradford protein analysis kits (Biorad, Richmond, CAl. 
Calculations and Statistics Drug results were calculated by comparison 
with vehicle control hydrolysis (% hydrolysis of drug treated samples/% 
hydrolysis of vehicle controls) - 1 X 100) and expressed as percent inhibi-
tion or as an inhibitory concentration [50] ICso value generated through 
linear regression analysis of a drug concentration versus hydrolysis plot. Data 
are expressed as mean ± SD of three determinations unless otherwise stated. 
All experiments were carried out 2 - 3 times representing 2 - 3 different 
keratinocyte preparations. 
RESULTS 
Characterization ofKeratinocyte sn-2 
Acylhydrolase Activities 
Biochemical Characterization of Human Keratinocyte Cyt050lic and Mi-
crosomal Fractions: Cells were disrupted and fractionated in EGT A, 
Ca++-free homogenization buffer to favor the localization of the 
85-kDa-like PLA2 activity in the cytosolic fraction [16,35]. Both 
fractions were examined using biochemical tools that would iden-
tify and delineate 14-kDa PLA2 from 85-kDa PLA2 activity. The 
type II 14-kDa PLA2 contains seven disulfide bonds in its tertiary 
structure that convey stability to heat treatment [9,36]. Exposure to 
sulfhydryl reducing agents such as dithiothreitol (DTT) destabilizes 
the enzyme resulting in a loss of activity [37]. The 85-kDa PLA2 is 
not affected by exposure to sulf11ydryl reducing agents but is very 
sensitive to high temperatures [16]. To identify the PLA2 activities 
present in the keratinocyte fractions, purified enzymes or cell frac-
tions were treated with water or DTT (10 mM, 37° C) for 30 min or 
incubated at 57 °C for 5 min. Samples were then assayed for 5rl-2 
acyl hydrolytic activity by the addition of the [3H]-AA E. coli as 
described in Materials and Methods. DTT totally inactivated the rh 
type II 14-kDa PLA2 but had no effect on the U937 85-kDa PLA2 
(Fig 1a). Approximately half of the activity in the keratinocyte 
microsomal fraction was inactivated by DTT treatment, whereas 
the cytosolic activity was not affected (Fig Ib) . Heat treatment did 
not effect the rh type II 14-kDa PLA2 but totally inactivated the 
U937 85-kDa PLA2 (Fig 1a). Approximately 70% of the activity in 
the cytosolic fraction was heat sensitive whereas 40 - 50% of the 
microsomal activity was inactivated by this treatment (Fig 1b). 
Unlike the 85-kDa PLA2, which is acid labile [17]. the 14-kDa 
PLA2 is resistant to acid treatment [16]. Therefore, the effect of 
exposure to an equal volume of 0.36 N H 2S04 (pH 2) or water (1 h 
at 4 ° C) on sn-2 acyl hydrolytic activity of keratinocyte microsomes 
or cytosol was studied. After acid treatment, the pH of the prepara-
tions was re-adjusted to pH 7.4 by addition of 2 M Tris (pH 10 for 
acid-treated samples and pH 7.4 for controls) and the samples were 
assayed for activity with the addition of [3H]-AA E. coli. The U937 
85-kDa PLA2 but not the rh type II 14-kDa PLA2 was inactivated by 
acid treatment (Fig 2a). Hydrolytic activity in the keratinocyte 
microsomes and cytosol was reduced 86% or 82%, respectively 
(Fig 2b) . 
The U937 85-kDa PLA2 exhibits a preference for arachidonic 
acid over less unsaturated fatty acids residing in the sn-2 position of 
substrate phospholipid [8,16,36]. Acylhydrolytic activity measured 
in keratinocyte cytosolic or microsomal fractions was compared 
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using radiolabeled PC vesicles (3.4 nmoljPi/assay) containing ei-
ther (14C]-0Ieate or (14C]-AA in the sn-2 position. The use of PC 
vesicles readily detects 85-kDa PLA2 activity but is a poor substrate 
for type II 14-kDa PLA2 [9,16]. Table I shows that the 85-kDaPLA2 
displayed a twelvefold preference for (14C]-AA PC over (14C]-oleate 
Pc. Type II 14-kDa PLA2 did not exhibit hydrolytic activity against 
either substrate, which is consistent with its preference for PE over 
PC as substrate. The activity in the keratinocyte microsomal frac-
tion exhibited a fourfold greater hydrolysis of the [14C]-AA PC 
vesicles over the [14C]-oleate PC vesicle. Under identical condi-
tions, the cytosolic fraction displayed a sevenfold greater hydrolytic 
activity against the (14C]-AA PC than the (14C]-oleate PC vesicles. 
To specifically evaluate the presence and contribution of a type II 
14-kDa PLA2 to the activity measured in the human keratinocyte, 
the cytosolic and microsomal fractions were incubated with the 
mouse SKF-3FIO MoAb generated against rh type II 14-kDa PLA2 • 
This MoAb neutralizes rh type II 14-kDa PLA2 hydrolytic activity 
in a concentration-dependent manner and is specific displaying no 
effect on 85-kDa PLA2 or type I 14-kDa PLA2 [38]. Figure 3a 
illustrates that exposure to 1 ,ug MoAb 3F10/assay for 60 min at 
37"C specifically interfered with the activity of rh type II 14-kDa 
PLA2 , reducing hydrolysis by 96%. In contrast, the activity of the 
U937 85-kDa PLA2 was not affected. Activity measured in kerati-
nocyte cytosol or microsomes was not significantly altered by expo-
sure to the neutralizing MoAb (Fig 3b) . This finding indicates that 
the sn-2 acyl hydrolase activity present in the keratinocyte fractions 
is not immunologically related to rh type II 14-kDa PLA2• 
Western Immurloblot Analysis: Cultured human keratinocyte mi-
crosomal and cytosolic fractions were subjected to sodium 
dodecylsulfate-polyacrylamide gel electrophoresis analysis and 
probed with anti-rh type II 14-kDa PLA2 MoAb 3F10 or anti-85-
kDa PLA2 rabbit serum. It is our experience that microsomal protein 
alters the migration of rh type II 14-kDa PLA2 compared to that of 
purified enzyme. Samples "spiked" with purified enzyme are there-
fore included to monitor migration of standard with the subcellular 
a. 
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Figure 1. Effect of the sulfhydryl reducing agent DTT and heat treatment 
on m-2 acyl hydrolytic activity of type II 14-kDa and U937 85-kDa purified 
PLA2 enzymes (a) and keratinocytc microsome and cytosol (b). Fractions 
were incubated in the presence ofO (solid bars) or 10 mM DTT (striped bars) 
for 30 min at 37 °C or incubated at 57"C for 5 min (dotted bars) prior to the 
addition of [JH]_AA E. coli as described in Materials a"d Methods. Bars, 
mean ± SD values of three determinations. Activity of purified enzyme was 
measured over 10 min and cell fractions were measured over 60 min. 
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figure 2. Effect of acid treatment on sll-2 acyl hydrolytic activiry of rype II 
14-kDa and U937 85-kDa purified PLA2 enzymes (a) and keratinocyte 
microsome and cytosol (b). Each fraction was exposed to an equal volume of 
0.36 N H 2S04 (acid, striped bars) or water (control, solid bars) for 1 hat 4°C. 
'The mixture was returned to pH 7.4 by the addition of2 M 'Tris and assayed 
for activiry using ['H]-AA E. coli (see Materials alld Methods). Bars, mean ± 
SD values of three determinations. Activiry of purified enzyme was mea-
sured over 10 min and cell fractions were measured over 60 min. 
fraction. Figure 4a shows that the human keratinocyte cytosolic 
frac tion [lane 6, 25,ug; lane 7 , 50,ug; lane 8, 50 ,ug with rh 85-kDa 
PLA2 (0.8 ,ug)] possesses a high-molecular-weight protein recog-
nized by rabbit anti - 85-kDa PLA2 serum and co-migrates with the 
rh 85-kDa PLA2 protein at 110 kDa (lanes 1,5, and 9). Immuno-
blots of the microsome [lane2, 25 ,ug; lane 3, 50,ug; lane 4, 50 ,ug 
with rh 85-kDa PLA2 (0.8 ,ug) revealed no immunoreactive proteins 
at 110 kDa. Probing the gels w ith mouse MoAb 3Fl0 (Fig 4B) 
revealed no immunologically related low - molecular-mass proteins 
in the microsome (lane 2, 25 ,ug; lane 3, 25 ,ug with rh type II 
14-kDa PLA2 (1 ,ug), and lane 4, 50,ug) or cytosol [lanes 6 and 7 (25 
and 50 ,ug, respectively) fractions]. 
Table I. Demonstration of sn-2 Fatty Acyl 
Preference by Activities Measured in Human 
Keratinocyte Microsome and Cytosol" 
Substrate 
Enzyme Sourceb., [1 4C]-Oleate-PC (14C]-AA-PC 
U937 85-kDa PLA2 2.3 ± 0.1 nmolj 27.9 ± 0.1 nmol/ 
min/mg min/mg 
rh type II 14-kDA NN NA 
PLA2 
Keratinocyte 11.5 ± 1.1 pmolj 33.0 ± 0.7 pmol/ 
microsome min/mg min/mg 
Keratinocyte 48.0 ± 9.7 pmolj 329.0 ± 20.4 pmol/ 
cytosol min/mg min/mg 
• Human keratinocyte microsome and cytosol were analyzed for activity using [14C]-
oleate or p4C]-AA PC vesicles as substrate and compared to rh 14-kDa PLAz and rU937 
85-kDa PLAz. Results are expressed as mean ± SD specific activity. 
• Enzymes were assayed for 10 min (Std) or 60 min (cell fractions) to obtain values on 
the linear portion of the activity curve. 
, Microsome and cytosol, prepared as described in Methods, were assayed as 20 and 
40 ILg of protein, respectively per assay over 60 min. 
I NA. no activity above background. 
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Figure 3. Effect of 3F10 rh rype II 14-kDa PLA2 neutralizing MoAb on 
sll-2 acyl hydrolytic activiry of rype II 14-kDa and U937 85-kDa purified 
enzymes (a) and keratinocyte microsomal and cytosolic fractions (b). Each 
fraction was exposed to 1 jig of 3F10 MoAb for 60 min at 37"C in assay 
buffer prior to the addition of [3H] AA E. coli substrate as described in 
Materia ls alld Methods. Bars, mean ± SD values of three determinations. Ac-
tiviry of purified enzyme was measured over 10 min and cell fractions were 
measured over 60 min. 
Further Evaluation of 511- 2 Acylhydrolytic Activity in Keratinocyte Cyto-
sol Fractions: Our characterization thus far established the presence 
of a biochemically simi lar 85-kDa - like PLA2 activity located pre-
dominately in the cytosol. The keratinocyte cytosolic activity was 
therefore further examined in the presence of submicromolar con-
centrations of Ca++ prepared in 1 mM EGT A buffers or buffer alone 
(no Ca++). Fig 5 shows that the cytosol did not hydrolyze [H]-AA-
E. coli in the absence of Ca++ but responded significantly (60- 70% 
maximal activity) to CA++ levels of 0.5-100 ,uM. This was 
fo llowed by a still greater increase at 1 mM CA ++ ("maximal 
activity"). 
The effect of selective 85-kDa PLA2 and 14-kDa PLA2 inhibitors 
on keratinocyte cytosol 511-2 acyl hydrolase activity was examined. 
The C-7 phosphonate phospholipid (C-7 PP), a selective phospho-
Table II. Effect of Selective and Non-Selective 14-kDa and 85-
kDa PLA2 Inhibitors on 511-2 Acylhydrolase Activity Measured in 
Human Keratinocyte Cytosolic Fractions 
Inhibitors [ jiM]' 
No drug 
C7 phosphonate PL 
30 jiM 
3 jiM 
AACOCF3 
30 jiM 
3 jiM 
Enzyme Activiry (% Acylhydrolysis)d 
U937 85-kDa PLA2b 
8.3 ± 0.5 
9.2 ± 0.3 
9.4 ± 0.3 
0.3 ± 0.3 
0.7 ± 0.1 
Keratinocyte Cytosol' 
10.4 ± 2.6 
9.0 ± 1.4 
8.9 ± 0.7 
2.0 ± 1.1 
2.3 ± 1.1 
• Compounds solubilized in ethanol and added as 10% of assay 10 min prior to 
initiating the assay. 
I Enzymes assayed for 10 min to obtain values on the linear portion of the activity 
curve. 
, Cytosol prepared as described in Materials .lId Methods. Thirty-four micrograms of 
protein per assay per 30 min. 
, Percent hydrolysis of PC over time (20 JiM PLPijassay). 
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116 kDa-
105 kDa-
B. 
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18 kDa-
Figure 4. Western analysis of microsomal and cytosolic fractions of human 
keratinocytes . Keratinocyte subcellular fractions were applied to a sodium 
dodecylsulfate - polyacrylamide gel electrophoresis gel (10 - 20%), trans-
ferred to nitrocellulose, and blotted with either the rabbit antisera NS1 made 
against the 85-kDa PLA2 (A) orthe MoAb 3FI0 made aga inst type II 14-kDa 
PLA2 (B) . Lanes in A are as fo llows: 1, 5, 9, rh U937 85-kDa PLA2 (0. 86,ug 
cytosolic protein); 2, microsome (25 ,ug); 3, microsome (50 ,ug); 4, micro-
some (50 ,ug) with rh 85-kDa PLA2 ; 6, cytosol (25,ug); 7, cytosol (50,ug); 8, 
cytosol (50,ug) with rh 85-kDa PLA2 • Lalles in B are as follows: 2, 6, 9, rh 
type II 14-kDa PLA2 ; 3, microsome (25,ug); 4, microsome (25 ,ug) with rh 
type II 14-kDa (0.5 ,ug) PLA2 ; 5, microsome (50 /lg) ; 7, cy tosol (25 /lg) ; 8, 
cytosol (50,ug). 
lipid transition state analog 14-kDa PLA2 inhibitor [19]' and the 
85-kDa PLA2 inhibitor trifloromethyl ketone (TFMK [20]) were 
evaluated for their effects on keratinocyte cytosolic ac tivity. U937 
85-kDa PLA2 or keratinocyte cytosol were exposed to vehicle or 
drug (10 min, 27°C) and then assayed for sn-2 acyl hydrolysis by the 
addition of substrate as described in Materials arId Methods. Table II 
shows the selective action of the TFMK against the U937 85 PLA2 
whereas the C-7 PP exhibited no effect as has been previously re-
ported [19] . Treatment of the cytosol with C-7 PP did not effect 
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Figure 5. Effect of free calcium concentrations on keratinocyte cytosolic 
hydrolysis of [3H] AA E. coli, assayed with or without EGTA. Cytosolic 
activity was analyzed in the presence of O,uM to 1 mM free Ca-. The zero 
Ca- point was generated by the addition of 1 mM EGTA and no Ca- (see 
Materials a/Jd Methods). The data represent mean ± SD values of triplicate 
determinations of two experiments. 
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Figure 6. Effect of inhibitors PGE2 release from cultured human keratino-
cytes. a shows the effect of veh ide or various concentrations of dexametha-
sone for 18 h at 37 °C priorto stimulation with A23187 (1 ,uM) for 15 min at 
37°C. Cells were exposed to vehicle or various concentrations of indometh-
acin (c), zileuton (c), or 12 epi-SLD (b) for 10 min at 27°C prior to stimula-
tion w ith A23187 (1 ,uM) for 15 min at 37°C as described in Materials a/Jd 
Methods. Values are expressed as mean ± SD (n = 3) percent of stimulated 
control vehicle values, which were 671.5 ± 86.9 pg PGE2/well (n = 3) (0) ; 
930 ± 11.3 pg PGE2/well (n = 3) (b) , 503 ± 83.4 pg PGE2/well (n = 3) (c) . 
'Significantly different from treated control p > 0.05 as determined by 
analysis of variance and Duncan multiple range analys is. 
activity. The cytosolic activity was significantly reduced when ex-
posed to TFMK at both concentrations. 
Evaluation oj Inhibitors 0 11 A23 187-Stimulated Keratinocyte PGE2 
Production: Human keratinocytes were cultured in 24-well plates 
as described in Materials and Methods and when confluent were 
preincubated with different concentrations of the glucocorticoster-
oid, dexamethasone, the selective , cell penetrable 14-kDa PLA2 
inhibitor 12 epi-SLD (38]' the cyclooxygenase inhibitor, indo-
methacin, or the 5-lipoxygenase (5-LO) inhibitor zileutin for 10 
min at room temperature prior to stimulation with 1 pM A23187 at 
37 ° C for 15 min. The C-7 PP could not be used because it has little 
or no effect on whole cells [19] . The TFMK was not used due to 
supply limitations and the fact that its effects on other AA metabo-
lizing enzymes (e.g., 5-LO, CoA-independent transacylase) were 
not known. The glucocorticosteroid, dexamethasone, was incu-
bated with cells for 24 h at 37"C in 5% CO2 atmosphere prior to 
stimulation with A23187 (15 min) . The medium was evaluated for 
the presence of PGE2 as described in Materials arid Methods. U nstim-
ulated cells incubated over 25 min contained from 503 ± 83 to 
930 ± 11 pg PGE2/250 ,Ill, whereas untreated cells incubated over-
night released 671.5 ± 86.9 pg PGE2/250 pI. Fig 6 shows that 
neither 12 epi-SLD (b) nor zileuton (c) significantly affected PGE2 
production at concentrations as high as 10 pM. Indomethacin at 
both concentrations totally reduced PGE2 release. Keratinocyte 
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pGEz release was inhibite? b~ dexamethasone (Fig 6a) in a concen-
tration-related manner, yleldmg an ICso value of 0.05 JlM. 
DISCUSSION 
Buman keratinocyte has been shown to possess SI,-2 acyl hydrolytic 
activity but the exact nature of the enzyme has not been clearly 
defined. Due to the recent identification of the novel 85-kDa PLA2 , 
we characterized the human keratinocyte SI1-2 acyl hydrolase activi-
ties in an effort to identify the enzymes responsible for AA libera-
tion and subsequent PGE2 formation. Using AA-radiolabeled PC 
vesicles the specific activity found in the cytosol and microsome was 
329 pmol/min/mg and 33 pmol/min/mg, respectively, suggesting 
that the cytosol possessed most of the acylhydrolase activity. Alter-
natively, because of the different substrate specificities exhibited by 
the tvVO human enzymes, it is difficult to quantitate relative distri-
butions using activity measurement only [35] . Here we have pro-
vided evidence that human keratinocytes exhibit an HI-2 acylhy-
drolase activity that is biochemically, immunologically, and phar-
macologically identical to the 85-kDa PLA2. The activity in the 
cytosol was not affected by DTT treatment, was significantly re-
duced after exposure to heat, and was completely abolished after 
acid treatment. In addition, this activity demonstrated a preference 
for AA in the SII-2 position of the PL substrate, was active at nano-
molar concentrations of calcium, and was inhibitable by a selective 
85-kDa PLA2 inhibitor but not the 14-kDa TSA inhibitor. Finally, 
i[JllTI.Unoblot analysis revealed a high - molecular-mass protein co-
migrating with rh 85-kDa PLA2 • 
The activity in the microsomal fraction behaved similarly to the 
cytosolic activity in that it was significantly reduced when exposed 
to heat, lost 82% of its activity after treatment with acid, and also 
demonstrated a preference for AA in the SII-2 position of the PL. The 
possibility that the 85-kDa-PLA2 activity migrated to the mem-
brane fractions in response to cell processing prior to fractionation 
cannot be ruled out. Alternatively, the microsmal activity was re-
duced 50% when exposed to DTT, suggesting the existence (albeit 
minor) of a non - 85-kDa-like PLA2• The keratinocyte microsomal 
activity was not affected by exposure to the MoAb 3FI0, indicating 
that an immunologically related type II 14-kDa PLA2 did not con-
tribute to the activity measured in keratinocyte microsome. We feel 
this is not due to the MoAb because it has been used successfully to 
neutralize PLA2 activity in other human cell types, such as the 
neutrophil, where type II 14-kDa PLA2 has been characterized [38]. 
These findings were further supported by the Western analysis that 
fai led to identify an immunologically related type II 14-kDa PLA2 
protein in either fraction. The MoAb 3F10 will not detect type I 
14-kDa PLA2, so the possibility that a type I 14-kDa PLA2 exists 
cannot be ruled out. At this time the exact nature of the microsomal 
5n-2 acyl hydrolase activity is not clear. 
In the keratinocyte whole cell studies, as expected, indomethacin 
inhibited PGE2 whereas zileuton did not. Currently, a selective 
85-kDa PLA2 inhibitor other than TFMK does not exist and the 
lack of knowledge on its effects on other AA metabolizing enzymes 
would complicate the use of this reagent. We therefore choose to 
use 12-epi SLD to further support the lack of a type II 14-kDa -like 
PLAz in the keratinocyte. In our hands 12-epi SLD did not alter 
A23187-induced PGE2 formation, which is consistent with our 
failure to identify this activity in these cells. Alternatively, exposure 
to dexamethasone after 24 h significantly reduced PGE2 release. 
Although dexmethasone is known to alter synthesis and release of 
cytokine-induced type II 14-kDa PLA2 [39] it has recently been 
shown to inhibit tumor necrosis factor-activated cytosolic 85-
kDa -like PLA2 activity [40]. Although one cannot rule out an 
effect of this steroid on the inducible cyclooxygenase II enzyme 
[41], the reduction in PGE2 could be due, in part, to the reduction in 
keratinocyte 85-kDa -like PLA2• Further work is needed to delin-
eate clearly the action of the steroid in the human keratinocyte. 
Recent abstracts by Gresham and co-workers have identified a 
high - molecular-mass PLA2 in the cytosol of human keratinocytes 
that increases with exposure to ultraviolet irradation [Greshem et al: 
Abstract. ] Invest Dermato! 100(14):595, 1993]. Our findings are 
KERATINOCYTE 85-kDa-LIKE PHOSPHOLIPASE Az 985 
in agreement with this as well as a recent report that described an 
increase in cytosolic PLA2 activity in ultraviolet-irradiated kerati-
nocytes. This activity exhibited a preference for AA in the sn-2 
position, supporting its similarity to the 85-kDa- like PLA2 isoform 
ll1]. In these studies the increase in PLA2 activity was associated 
with an increase in prostanoid release. Furstenberger et al reported 
evidence suggesting that a cytosolic PLA2 was responsible for the 
selective release of AA after stimulation with bradykinin [Fursten-
berger et af: Abstract. Cell Bioi (Suppl) 17 A, 285, 1993] . 
T aken together, the evidence for the role of the 85-kDa -like 
PLA2 in the release of arachidonic acid and its subsequent metabo-
lism to prostanoids by human keratinocytes is increasing. The im-
plication of this for novel drug therapy through modification or 
attenuation of this enzyme are currently under investigation. 
We wOllld like to tltatlk Dr. Edward Appleballm Jor rabbit antibody against the 
85-kDa PLA2, LYtlette McMillet, alJd Kate Fi,merty-Kaiser Jor preparilJg the 
MoAb 3F10, and Bria" Bolognese a"d A my R osltakJor techtlical assistatlce atld 
advice. We t"atlk Holly Rayrnotld atld Dotti LavalJ Jar their excellem typitlg alJd 
proofreaditlg. 
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